Topical treatment or prevention of ocular infections

Details Topical treatment or prevention of ocular infections Topical treatment or prevention of ocular infections

2004-07-26

2010-06-08

Peselev, Elli (Department: 1623)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Carbohydrate doai

Reexamination Certificate

active

07732415

ABSTRACT:
The topical application of an azalide antibiotic such as azithromycin to the eye is useful in treating or preventing ocular infections. In one embodiment, the azalide antibiotic is supplied to the eye in a depot for sustained release. A more convenient dosing regimen can also be provided by the use of an appropriate depot. Furthermore, a composition containing a combination of medicaments is also provided.

REFERENCES:
patent: 4474768 (1984-10-01), Bright
patent: 4512982 (1985-04-01), Hauske et al.
patent: 4517359 (1985-05-01), Kobrehel et al.
patent: 4551456 (1985-11-01), Katz
patent: 4692454 (1987-09-01), Mich et al.
patent: 4851415 (1989-07-01), Mich et al.
patent: 5124154 (1992-06-01), Babcock et al.
patent: 5188826 (1993-02-01), Chandrasekaran et al.
patent: 5192535 (1993-03-01), Davis et al.
patent: 5225399 (1993-07-01), Zasloff et al.
patent: 5239059 (1993-08-01), Zasloff et al.
patent: 5250518 (1993-10-01), Kobrehel et al.
patent: 5340572 (1994-08-01), Patel et al.
patent: 5424290 (1995-06-01), Maloy et al.
patent: 5441939 (1995-08-01), Yang
patent: 5498699 (1996-03-01), Djokic et al.
patent: 5578572 (1996-11-01), Horwitz et al.
patent: 5605889 (1997-02-01), Curatolo et al.
patent: 5610198 (1997-03-01), Barry, III et al.
patent: 5631004 (1997-05-01), Cagle et al.
patent: 5679665 (1997-10-01), Bergamini et al.
patent: 5747058 (1998-05-01), Tipton et al.
patent: 5767153 (1998-06-01), Bowman et al.
patent: 5783561 (1998-07-01), Horwitz et al.
patent: 5804558 (1998-09-01), Lehrer et al.
patent: 5807830 (1998-09-01), Morozov et al.
patent: 5814655 (1998-09-01), Patel et al.
patent: 5872104 (1999-02-01), Vermeulen et al.
patent: 5888973 (1999-03-01), Lambert, Jr.
patent: 5912331 (1999-06-01), Wilkening
patent: 5977171 (1999-11-01), Bowman et al.
patent: 6159458 (2000-12-01), Bowman et al.
patent: 6239113 (2001-05-01), Dawson et al.
patent: 6265444 (2001-07-01), Bowman et al.
patent: 6277829 (2001-08-01), Asero et al.
patent: 6309630 (2001-10-01), Patel et al.
patent: 6378526 (2002-04-01), Bowman et al.
patent: 6397849 (2002-06-01), Bowman et al.
patent: 6569443 (2003-05-01), Dawson et al.
patent: 6861411 (2005-03-01), Ahmed
patent: 7056893 (2006-06-01), Roy et al.
patent: 2003/0143259 (2003-07-01), Roy et al.
patent: 2003/0171307 (2003-09-01), Boettner
patent: 0 126 684 (1984-11-01), None
patent: 0 142 426 (1985-05-01), None
patent: 0 298 650 (1989-01-01), None
patent: 0 391 909 (1990-10-01), None
patent: 0 445 743 (1991-09-01), None
patent: 0 445 743 (1991-09-01), None
patent: 0 467 331 (1992-01-01), None
patent: 0 677 530 (1995-10-01), None
patent: 0 679 400 (1995-11-01), None
patent: 0 711 546 (1996-05-01), None
patent: 0 879 823 (1998-11-01), None
patent: 0 925 789 (1999-06-01), None
patent: 0925 789 (1999-06-01), None
patent: 1075837 (2001-02-01), None
patent: 11-240838 (1999-09-01), None
patent: 89/00576 (1989-01-01), None
patent: 95/09601 (1995-04-01), None
patent: 96 19489 (1996-06-01), None
patent: 96 20010 (1996-07-01), None
patent: 96/39995 (1996-12-01), None
patent: WO 98/17280 (1998-04-01), None
Bailey et al., Lancet vol. 3rdpp. 453-456 (1993).
First Meeting of the WHO Alliance for the Global Elimination of Trachoma, Geneva, Jun. 30-Jul. 1, 1997.
Robert E. Leonard, II et al.,Erythromycin, Clarithromycin, and Azithromycin, 1997, Textbook of Ocular Pharmacology, pp. 515-523.
Robert H. Cross, et al.Corneal Pharmacokinetics of Topical Clarithromycin, Apr. 1995, Investigative Ophthalmology & Visual Science, vol. 36, No. 5, pp. 965-968.
Drug Approvals for Jan. 1997, Center for Drug Evaluation and Research, USDA (p. 1, 2; thromax).
Zithromax for IV Infusion Only, Pfizer Labs, New York, NY (2001).
International Search Report PCT/US00/07924, European Patent Office Mar. 14, 2001.
A comparison of oral azithromycin with topical oxytetracycline/polymyxin for the treatment of trachoma in children. Abstract XP-002161953, Biosis Information Service, Philadelphia, PA, 1997.
Oral vs. topical erythromycin therapies for chlamydial conjunctivitis. Abstract XP-002161954, Biosis Information Service, Philadelphia, PA, 1982.
Corneal pharmacokinetics of topical clarithromycin. Abstract XP-002161955, Biosis Information Service, Philadelphia, PA, 1995.
Jururatanasirikul, S., et al.,Distribution of azithromycin into brain tissue, cerebrospinal fluid, and aqueous humor of the eye. Antimicrobial Agents Chemotherapy, 40:825-826(1996).
Thylefors, B.Azithromycin: A new opportunity for control of trachoma. WHO Drug Information 10(3):132-133 (1996).
Programme for the Prevention of Blindness and Deafness Alliance for the Global Elimination of Trachoma, “Planning for the Global Elimination of Trachoma (GET) Report of the WHO Consultation”, Geneva, Switzerland (Nov. 25 & 26, 1996).
Programme for the Prevention of Blindness and Deafness Alliance for the Global Elimination of Trachoma, “Report of the First Meeting of the WHO Alliance for the Global Elimination of Trachoma”, Geneva, Switzerland (Jun. 30-Jul. 1, 1997).
Programme for the Prevention of Blindness and Deafness, “Report of the Second Meeting of the WHO Alliance for the Global Elimination of Trachoma”, Geneva, Switzerland (Jan. 12-14, 1998).
Prevention of Blindness and Deafness Geneva, Switzerland, “Report of the Third Meeting of the WHO Alliance for the Global Elimination of Trachoma”, Quarzazate, Morocco (Oct. 19-20, 1998).
Azithromycin, Official Monographs, USP, vol. 25, pp. 188-190.
Dawson et al,A comparison of Oral Azithromycin with Topical Oxytetracycline/Polymyxin for the Treatment of Trachoma in Children, Clinical Infections Diseases 1997:24 (Mar.) 363-368 (full copy).

Affiliated with

Also associated with

Rating

Topical treatment or prevention of ocular infections does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Topical treatment or prevention of ocular infections, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Topical treatment or prevention of ocular infections will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4201878